Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.
《肺癌》是一本国际性刊物，涵盖肺和胸部恶性肿瘤的临床、转化和基础科学。欢迎发表涵盖肺癌预防、流行病学和病因学、基础生物学、病理学、临床评估、手术、化疗、放疗、联合治疗模式、其他治疗模式和结局的原创研究文章、早期报告、综述文章、社论和通信。
Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.01.010
A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.09.011
PTEN inactivation induces epithelial-mesenchymal transition and metastasis by intranuclear translocation of β-catenin and snail/slug in non-small cell lung carcinoma cells.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.01.013
Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.04.008
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.04.005
Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.08.006
Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2018.11.039
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.02.020
Real-world effectiveness and safety of nivolumab in patients with non-small cell lung cancer: A multicenter retrospective observational study in Japan.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.11.014
CNS metastasis in ROS1+ NSCLC: An urgent call to action, to understand, and to overcome.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.02.025
Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: A meta-analysis.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.07.010
Predictive value of a prognostic model based on pathologic features in lung invasive adenocarcinoma.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.03.002
Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.11.022
Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.05.032
Quality of life analysis in lung cancer: A systematic review of phase III trials published between 2012 and 2018.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.10.022
Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.02.001
Paired genomic analysis of squamous cell carcinoma transformed from EGFR-mutated lung adenocarcinoma.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.05.024
PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.01.004
A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.05.030
First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.04.006
Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2018.11.022
Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC).
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2018.12.009
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.10.015
Imaging in pleural mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2018.11.033
DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.10.010
Phase I safety and pharmacokinetics study of rovalpituzumab tesirine in Japanese patients with advanced, recurrent small cell lung cancer.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.07.025
Capitalizing on a teachable moment: Development of a targeted self-help smoking cessation intervention for patients receiving lung cancer screening.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.02.014
The incidence of lymph node metastasis in patients with different oncogenic driver mutations among T1 non-small-cell lung cancer.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.06.026
Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2018.11.026
UPSTAGING, CENTRALITY AND SURVIVAL IN EARLY STAGE NON-SMALL CELL LUNG CANCER VIDEO-ASSISTED SURGERY.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.06.030
Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.02.023
Patient-reported outcomes (PROs) in lung cancer: Experiences from a nationwide feasibility study.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2018.12.014
IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.02.027
Association of oral health with lung cancer risk in a low-income population of African Americans and European Americans in the Southeastern United States.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2018.11.028
Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.05.034
Endobronchial and surgical treatment of pulmonary carcinoid tumors: A systematic literature review.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.04.016
Hospital lung surgery volume and patient outcomes.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.01.002
Prognostic significance of blood and lymphatic vessel invasion in pathological stage IA lung adenocarcinoma in the 8th edition of the TNM classification.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.09.022
Prognostic factors of acinar- or papillary-predominant adenocarcinoma of the lung.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.09.026
Patient reported outcome data as performance indicators in surgically treated lung cancer patients.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.02.010
Lung cancer survivors and employment: A systematic review.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.03.010
A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.08.009
Molecular profiling of thymoma with myasthenia gravis: Risk factors of developing myasthenia gravis in thymoma patients.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.11.007
Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.05.023
Decreased cardiovascular mortality in the ITALUNG lung cancer screening trial: Analysis of underlying factors.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.10.006
Clearing of circulating tumour DNA predicts clinical response to first line tyrosine kinase inhibitors in advanced epidermal growth factor receptor mutated non-small cell lung cancer.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.12.016
Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.05.007
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
来源期刊：Lung cancerDOI：10.1016/J.LUNGCAN.2019.07.021
A case of primary lung squamous cell carcinoma mimicking malignant mesothelioma producing granulocyte colony stimulating factor with chemotherapy (cisplatin and gemcitabine)-associated thrombotic thrombocytopenic purpura (TTP); An autopsy case report.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.08.018
Clinical implications of uncertain resection in scenarios of metastasis of the highest or most distant mediastinal lymph node station following surgical treatment of non-small-cell lung cancer.
来源期刊：Lung cancerDOI：10.1016/j.lungcan.2019.09.018
